Vicore Pharma Holding AB (publ)

OM:VICO Stock Report

Market Cap: SEK 1.8b

Vicore Pharma Holding Valuation

Is VICO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VICO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VICO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VICO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VICO?

Key metric: As VICO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VICO. This is calculated by dividing VICO's market cap by their current revenue.
What is VICO's PS Ratio?
PS Ratio17.5x
SalesSEK 104.24m
Market CapSEK 1.83b

Price to Sales Ratio vs Peers

How does VICO's PS Ratio compare to its peers?

The above table shows the PS ratio for VICO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average17.6x
HNSA Hansa Biopharma
10.7x47.3%SEK 2.0b
EGTX Egetis Therapeutics
28.6x81.7%SEK 1.9b
DVYSR Devyser Diagnostics
11x31.3%SEK 2.2b
CRNO B Cereno Scientific
20.1x-171.4%SEK 1.4b
VICO Vicore Pharma Holding
17.5x-98.7%SEK 1.8b

Price-To-Sales vs Peers: VICO is good value based on its Price-To-Sales Ratio (17.5x) compared to the peer average (17.6x).

Price to Sales Ratio vs Industry

How does VICO's PS Ratio compare vs other companies in the SE Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
XBRANE Xbrane Biopharma
1.5x61.1%US$27.38m
SPRINT Sprint Bioscience
1.7x27.6%US$9.61m
PMDS PMD Device Solutions
0.8x62.0%US$3.00m
GEAN Genetic Analysis
1xn/aUS$1.83m
VICO 17.5xIndustry Avg. 11.8xNo. of Companies6PS0816243240+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VICO is expensive based on its Price-To-Sales Ratio (17.5x) compared to the Swedish Biotechs industry average (11.8x).

Price to Sales Ratio vs Fair Ratio

What is VICO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VICO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio17.5x
Fair PS Ratio0.04x

Price-To-Sales vs Fair Ratio: VICO is expensive based on its Price-To-Sales Ratio (17.5x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VICO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 7.78
SEK 33.25
+327.4%
23.6%SEK 40.00SEK 20.00n/a4
Nov ’25SEK 8.00
SEK 35.99
+349.9%
8.1%SEK 40.00SEK 32.00n/a4
Oct ’25SEK 7.81
SEK 36.32
+365.1%
9.1%SEK 40.00SEK 32.00n/a3
Sep ’25SEK 16.46
SEK 50.50
+206.8%
30.1%SEK 70.00SEK 32.00n/a4
Aug ’25SEK 17.90
SEK 61.50
+243.6%
31.0%SEK 84.00SEK 32.00n/a4
Jul ’25SEK 20.05
SEK 61.50
+206.7%
31.0%SEK 84.00SEK 32.00n/a4
Jun ’25SEK 22.00
SEK 61.50
+179.5%
31.0%SEK 84.00SEK 32.00n/a4
May ’25SEK 18.06
SEK 61.50
+240.5%
31.0%SEK 84.00SEK 32.00n/a4
Apr ’25SEK 14.68
SEK 61.50
+318.9%
31.0%SEK 84.00SEK 32.00n/a4
Mar ’25SEK 14.38
SEK 68.60
+377.1%
32.3%SEK 97.00SEK 32.00n/a5
Feb ’25SEK 13.30
SEK 70.75
+432.0%
34.4%SEK 97.00SEK 32.00n/a4
Jan ’25SEK 14.18
SEK 70.75
+398.9%
34.4%SEK 97.00SEK 32.00n/a4
Dec ’24SEK 15.38
SEK 70.75
+360.0%
34.4%SEK 97.00SEK 32.00n/a4
Nov ’24SEK 12.72
SEK 70.75
+456.2%
34.4%SEK 97.00SEK 32.00SEK 8.004
Oct ’24SEK 15.30
SEK 70.75
+362.4%
34.4%SEK 97.00SEK 32.00SEK 7.814
Sep ’24SEK 15.58
SEK 70.75
+354.1%
34.4%SEK 97.00SEK 32.00SEK 16.464
Aug ’24SEK 18.28
SEK 70.75
+287.0%
34.4%SEK 97.00SEK 32.00SEK 17.904
Jul ’24SEK 17.12
SEK 70.50
+311.8%
35.1%SEK 97.00SEK 31.00SEK 20.054
Jun ’24SEK 17.66
SEK 72.00
+307.7%
31.0%SEK 97.00SEK 31.00SEK 22.005
May ’24SEK 19.16
SEK 70.00
+265.3%
29.8%SEK 97.00SEK 31.00SEK 18.066
Apr ’24SEK 18.36
SEK 70.00
+281.3%
29.8%SEK 97.00SEK 31.00SEK 14.686
Mar ’24SEK 14.84
SEK 70.00
+371.7%
29.8%SEK 97.00SEK 31.00SEK 14.386
Feb ’24SEK 16.66
SEK 74.67
+348.2%
31.2%SEK 98.00SEK 31.00SEK 13.306
Jan ’24SEK 17.90
SEK 83.40
+365.9%
16.7%SEK 98.00SEK 60.00SEK 14.185
Dec ’23SEK 24.25
SEK 83.40
+243.9%
16.7%SEK 98.00SEK 60.00SEK 15.385
Nov ’23SEK 29.50
SEK 80.40
+172.5%
15.4%SEK 97.00SEK 60.00SEK 12.725

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

AstraZeneca

UK£154.5b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,413.50

7D

-1.8%

1Y

4.5%

PMD Device Solutions

SEK 36.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.28

7D

-14.7%

1Y

n/a

Swedish Orphan Biovitrum

SEK 99.5b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.60

7D

-12.4%

1Y

15.7%